VIB VZW Patent applications |
Patent application number | Title | Published |
20160052999 | FUNCTIONAL HEAVY CHAIN ANTIBODIES, FRAGMENTS THEREOF, LIBRARY THEREOF AND METHODS OF PRODUCTION THEREOF - The present invention relates to functional heavy chain antibodies, functional single domain heavy chain antibodies, functional VH domains, or functional fragments thereof comprising an amino acid which is neither a charged amino acid nor a C at position 45, and comprising an amino acid at position 103 independently chosen from the group consisting of R, G, K, S, Q, L, and P, and optionally an amino acid at position 108 independently chosen from the group consisting of Q, L and R, said positions determined according to the Kabat numbering. | 02-25-2016 |
20150299672 | RESTORING PHOSPHORYLATION OF A NOVEL PINK1 SUBSTRATE TO TREAT PARKINSON'S DISEASE - The present application relates to the field of Parkinson's disease (PD), particularly sporadic PD or PD associated with mutations in the mitochondrial kinase PINK1. A new substrate for this kinase, NdufA10, is identified herein. In Parkinson's disease, this protein is dephosphorylated, which is linked to a loss of mitochondrial membrane potential. It is shown that restoring or mimicking phosphorylation of NdufA10 restores the phenotypic defects associated with Parkinson's disease and is thus a new therapeutic paradigm. | 10-22-2015 |
20150071940 | SINGLE DOMAIN ANTIBODIES CAPABLE OF MODULATING BACE ACTIVITY - Described are single domain antibodies with a specificity for BACE1. More specifically, described are single variable-domain antibodies derived from camelids that bind to BACE1 and are capable of inhibiting the activity of BACE1. The antibodies can be used for research and medical applications. Specific applications include the use of BACE1-specific antibodies for the treatment of Alzheimer's disease. | 03-12-2015 |
20140356871 | DIAGNOSTIC TESTS FOR THE DETECTION OF INHERITED PERIPHERAL NEUROPATHIES - The disclosure relates to the field of human genetics, particularly the field of peripheral neuropathy, particularly inherited peripheral neuropathy. Specifically, the disclosure relates to methods and materials to detect hereditary peripheral neuropathy, more particularly autosomal recessive Charcot-Marie-Tooth disease. | 12-04-2014 |
20140344996 | METHODS AND MEANS TO PRODUCE ABIOTIC STRESS TOLERANT PLANTS - This disclosure relates to the field of plant molecular biology and concerns methods for enhancing the abiotic stress tolerance in plants by modulating the expression of a gene involved in the gibberellin biosynthesis during the period of abiotic stress. This disclosure also provides chimeric constructs useful in the methods disclosed herein. In addition, transgenic plants having an enhanced abiotic stress resistance are provided herein. | 11-20-2014 |
20140325703 | METHODS AND MEANS FOR GENERATING MICROBIAL DISEASE RESISTANT PLANTS - Described are genes and chimeric genes encoding anti-microbial peptides. These genes can be used to generate transgenic plants with an improved resistance to, for example, plant pathogenic fungi. Alternatively, the peptides encoded by these genes can be applied as agrochemical formulations to plants suffering from microbial diseases such as fungal diseases. | 10-30-2014 |
20140294811 | METHOD FOR PREDICTING RISK OF HYPERTENSION ASSOCIATED WITH ANTI-ANGIOGENESIS THERAPY - The invention is concerned with a method of predicting a patient's susceptibility to developing hypertension associated with an anti-angiogenesis treatment, such as bevacizumab, by determining the genotype of KDR gene and/or EGF gene. The invention further relates to a pharmaceutical composition comprising an angiogenesis inhibitor, such as bevacizumab, for the treatment of a patient suffering from cancer based on the genotype of KDR gene and/or EGF. The invention further relates to a method for reducing the risk of hypertension associated with an anti-angiogenesis therapy, such as bevacizumab, in a patient suffering from cancer by determining the genotype of KDR gene and/or EGF gene. | 10-02-2014 |
20140220568 | MEANS AND METHODS FOR THE DETERMINATION OF PREDICTION MODELS ASSOCIATED WITH A PHENOTYPE - The disclosure provides methods and means for identifying plants comprising a plant phenotype of interest. In particular, the disclosure provides breeding tools that can be used for the selection of a plant comprising a phenotype of interest and for the selection of an optimal plant genotype for the introduction of a trait. | 08-07-2014 |
20140187741 | MEANS AND METHODS FOR MEDIATING PROTEIN INTERFERENCE - The present invention belongs to the field of functional proteomics and more particularly to the field of protein aggregation. The invention discloses a method for interfering with the function of a target protein and uses a non-naturally, user-designed molecule, designated as interferor, that has a specificity for a target protein and which induces aggregation upon contact with said target protein. The present invention also discloses such interferor molecules and their use in agrobiotech applications. | 07-03-2014 |
20140154738 | PROTEIN GLYCOSYLATION MODIFICATION IN METHYLOTROPHIC YEAST - The present invention provides genetically engineered strains of | 06-05-2014 |
20140143897 | EPHA4 IS A DISEASE MODIFIER IN MOTOR NEURON DISEASE - The present application relates to the field of motor neuron diseases, most particularly to amyotrophic lateral sclerosis and spinomuscular atrophy. Provided herein are strategies to improve symptoms and increase survival in patients with these axonopathies by inhibiting signaling mediated by the EphA4 ephrin receptor. | 05-22-2014 |
20140130208 | METHODS AND MEANS TO PRODUCE ABIOTIC STRESS TOLERANT PLANTS - The present invention relates to the field of plant molecular biology and concerns methods for enhancing the abiotic stress tolerance in plants by modulating the expression of a gene involved in the ethylene signal transduction pathway during the period of abiotic stress. The present invention also provides chimeric constructs useful in the methods in the invention. In addition, the invention provides transgenic plants having an enhanced abiotic stress resistance. | 05-08-2014 |
20140037646 | MMP8 INACTIVATING ANTIGEN BINDING PROTEINS - Described are MMP8 inactivating antigen binding proteins, such as antigen binding proteins comprising an amino acid sequence that comprises 4 framework regions and 3 complementary determining regions; further described is the use of such antigen binding proteins to treat inflammation, such as, but not limited to, systemic inflammatory response syndrome, sepsis, LPS induced inflammation, renal ischemia/reperfusion injury, ventilation induced lung injury, periodontal inflammation, rheumatoid arthritis, multiple sclerosis, ankylosing spondylitis, Lyme arthritis and osteoarthritis. | 02-06-2014 |
20140030746 | KINASE SUBSTRATE SENSOR - The disclosure relates to a cytoplasmic protein complex comprising: (a) a first recombinant fusion protein comprising a kinase, fused to a first interaction polypeptide; and (b) a second recombinant fusion protein comprising a domain comprising a reporter phosphorylation site, whereby the domain is fused to a second interaction polypeptide. The disclosure relates further to a method to detect compound-compound-interaction using the cytoplasmic protein complex, and to cells comprising such cytoplasmic protein complex. | 01-30-2014 |
20130345142 | DETECTING AND TREATING DEMENTIA - This document relates to methods and materials for detecting mutations that can be linked to dementia. For example, methods and materials for detecting one or more mutations within PGRN nucleic acid are provided. This document also provides methods and materials for detecting the level of progranulin expression. In addition, this document relates to methods and materials for treating mammals having a neurodegenerative disorder (e.g., dementia). For example, methods and materials for increasing PGRN polypeptide levels in mammals are provided, as are methods and materials for identifying agents that can be used to increase PGRN polypeptide levels in mammals. | 12-26-2013 |
20130330421 | COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING MELANOMA - The present disclosure relates to the field of oncology, more particularly to the field of melanoma. Provided are methods of treating melanoma, particularly advanced cutaneous melanoma, with a combination of pharmaceutical agents comprising MDM4-specific antagonists (such as an inhibitor of the MDM4-p53 interaction or a molecule that decreases MDM4 protein stability) or MDM4-MDM2 dual inhibitors (i.e., molecules that disrupt the interactions between p53 and MDM2 and p53 and MDM4) and one or more chemotherapeutic agents such as for example alkylating agents (i.e., Dacarbazine (DITC) or melphalan), alkylating-like agents (i.e., cisplatin or carboplatin) or mitotic inhibitors (taxanes docetaxel or paclitaxel) and PI3K-AKT, B-RAF and MEK inhibitors. Further provided are pharmaceutical formulations of MDM4-specific antagonists (be it an inhibitor of the MDM4-p53 interaction or a molecule that decreases MDM4 protein stability) or MDM4-MDM2 dual inhibitors (i.e., molecules that disrupt the interactions between p53 and MDM2 and p53 and MDM4) and a pharmaceutical formulation of one or more chemotherapeutic agents such as for example alkylating agents (i.e., Dacarbazine (DITC) or melphalan), alkylating-like agents (i.e., cisplatin or carboplatin) or mitotic inhibitors (taxanes docetaxel or paclitaxel) and B-RAF and MEK inhibitors. | 12-12-2013 |
20130315916 | RESPIRATORY SYNCYTIAL VIRUS VACCINE - Described is a vaccine against Respiratory Syncytial Virus (RSV). More specifically, described is a recombinant subunit vaccine comprising the ectodomain of the RSV-encoded Small Hydrophobic (SH) protein. The ectodomain of SH is referred to as SHe. The ectodomain is typically presented as an oligomer, or a pentamer. Further described are antibodies, raised against the ectodomain or specific for the ectodomain, and their use for protecting a subject against RSV infection and/or for treatment of an infected subject. | 11-28-2013 |
20130267426 | MICROSATELLITE INSTABILITY MARKERS IN DETECTION OF CANCER - The present application relates to the field of cancer, particularly to mismatch repair (MMR−) deficient tumors. New markers are presented herein that have a high sensitivity to detect whether a tumor is mismatch repair deficient or not. The markers are particularly mutations in microsatellite regions. Accordingly, methods are provided for diagnosing microsatellite instability of a tumor, comprising determining the presence of these markers. Further, kits are provided to detect the presence of these markers (or subsets thereof) in a sample. | 10-10-2013 |
20130246439 | METHOD AND SYSTEM FOR USING AN INFORMATION SYSTEM - A computer-implemented method and system for ranking information in an information system comprising linked objects is disclosed. The computer-implemented method comprises computing a prior ranking of all objects in the linked database, obtaining at least one source object, determining the probability of reaching an object taking a step in random walk with restart in the at least one source object(s) based on the adjacency between objects in the information system, and determining a ranking of objects in the information system using the determined probability and applying a correction factor inversely proportional with the computed prior ranking of the objects. An output based on the determined ranking is provided. The present invention also relates to a computer-implemented method and system for providing probable functional relations between at least one source object and a target object, as well as computer-related products therefor. | 09-19-2013 |
20130217572 | SPECIFIC DELIVERY OF AGROCHEMICALS - Described is the specific delivery of agrochemicals to plants. More specifically, described is a composition having a targeting agent comprising at least one binding domain that specifically binds to a binding site on an intact living plant and an agrochemical or a combination of agrochemicals. Also described is a binding domain that specifically binds the binding site on an intact living plant. More specifically, described are binding domains comprising a peptide sequence that comprises four framework regions and three complementary-determining regions, or any suitable fragment thereof, so that the binding domains are able to bind or retain a carrier onto a plant. Described are binding domains that specifically bind trichomes, stomata, cuticle, lenticels, thorns, spines, root hairs, or wax layer. Described is a method for delivery of agrochemicals to a plant, for improving the deposition of agrochemicals on a plant, and for retaining the agrochemicals on a plant, using targeting agents comprising the binding domains, and to a method for protecting a plant against biotic or abiotic stress or controlling plant growth using the same. Also, described is a method for manufacturing a specifically targeting agrochemical carrier. | 08-22-2013 |
20130195835 | Glycosylation of Molecules - Described herein are methods and genetically engineered cells useful for producing an altered N-glycosylation form of a target molecule. Also described are methods and molecules with altered N-glycosylation useful for treating a variety of disorders such as metabolic disorders. | 08-01-2013 |
20130191936 | GENE EXPRESSION SIGNATURE FOR THE SELECTION OF HIGH ENERGY USE EFFICIENT PLANTS - Means and methods are provided to produce abiotic stress tolerant with improved yield based on the specific identification of a gene expression signature in said plants out of a population of said plants. | 07-25-2013 |
20130190253 | Glycosylation of Molecules - Described herein are methods and genetically engineered cells useful for producing an altered N-glycosylation form of a target molecule. Also described are methods and molecules with altered N-glycosylation useful for treating a variety of disorders such as metabolic disorders. | 07-25-2013 |
20130158239 | HYDROLYSIS OF MANNOSE-1-PHOSPHO-6-MANNOSE LINKAGE TO PHOSPHO-6-MANNOSE - Described herein are methods and genetically engineered cells useful for uncapping a mannose-6-phosphate residue on an oligosaccharide. | 06-20-2013 |
20130149297 | ROLE OF FRAGILE X MENTAL RETARDATION GENE AND PROTEIN IN CANCER METASTASIS - The present application relates to the field of cancer. Surprisingly, it was shown that the Fragile X mental retardation gene (Fmr1) products such as the FMRP protein, primarily implicated in mental retardation, are upregulated in metastasizing tumours. It is shown how Fmr1 gene products can be used as a marker for cancer metastasis and how inhibition of these gene products may help prevent or reduce metastasis. | 06-13-2013 |
20130137140 | INCREASED PROTEIN EXPRESSION THROUGH INCREASED MEMBRANE FORMATION - The present application relates to the field of protein expression technologies. More specifically, it is demonstrated that cells with increased levels of phosphatidic acid, which can be achieved through either or both of phosphatidic acid inhibition and diacylglycerol kinase overexpression, display increased membrane formation from which increased levels of proteins can be recovered. | 05-30-2013 |
20130078224 | INDUCTION/MONITORING OF ARTERIOGENESIS USING SDF1 AND PDGFB OR INHIBITION OF PHD2 - The disclosure relates to the field of ischemia and how to increase tissue perfusion in ischemic tissue by cellular therapy. Specifically, the beneficial effects of myeloid (bone marrow-derived) cells with a particular arteriogenic gene expression profile are shown, and it is shown that increased arteriogenesis and perfusion is specifically due to the effects of combined PDGFB and SDF-1. The arteriogenic gene profile of the myeloid cells used for therapy can, for instance, be obtained by inhibition of PHD2. | 03-28-2013 |
20120331582 | METHOD TO CONTROL SPIDER MITES - The present invention relates to a method of controlling spider mites on plants. More specifically, the invention relates to plants expressing RNAi of one or more essential genes of the spider mite, and the use of those plants to control the spider mite proliferation into pest proportions. In a preferred embodiment, the spider mite is | 12-27-2012 |
20120301394 | TARGETING AND IN VIVO IMAGING OF TUMOR-ASSOCIATED MACROPHAGES - The invention relates to activities and characteristics of tumor-associated macrophages (TAMs). In particular, immunoglobulin single variable domains are provided against markers of TAMs, and methods using the same for in vivo imaging of tumor cells, as well as cancer diagnostics and therapeutics. | 11-29-2012 |
20120276076 | ARF6 AS A NEW TARGET FOR TREATING ALZHEIMER'S DISEASE - The invention relates to the field of disorders of the peripheral or central nervous system, in particular, Alzheimer's disease, and the prevention and/or treatment thereof. In particular, the invention relates to ARF6 and/or ARF6 effector proteins as new targets in Alzheimer's disease, and based thereon, screening methods for compounds that reduce amyloid beta peptide formation in mammalian cells by affecting ARF6-mediated endosomal sorting. | 11-01-2012 |
20120245326 | SPIDER MITE SILK PROTEINS - Described are silk proteins derived from spider mite, more specifically derived from | 09-27-2012 |
20120237526 | BACE1 INHIBITORY ANTIBODIES - The present invention relates to antibodies with a specificity for BACE1. More specifically, the invention provides monoclonal antibodies that bind to BACE1 and are capable of inhibiting the activity of BACE1 and methods producing these antibodies. The antibodies can be used for research and medical applications. Specific applications include the use of BACE1-specific antibodies for the treatment of Alzheimer's disease. | 09-20-2012 |
20120136045 | SCREENING FOR COMPOUNDS THAT MODULATE GPR3-MEDIATED BETA-ARRESTIN SIGNALING AND AMYLOID BETA PEPTIDE GENERATION - The invention relates to the field of disorders of the peripheral or central nervous system, in particular, Alzheimer's disease, and the prevention and/or treatment thereof. In particular, the invention relates to the screening of compounds that modulate GPR3 activity and/or beta-arrestin signaling in a mammalian cell and, in particular, compounds that reduce the formation of amyloid beta peptides. The invention also relates to inhibiting agents targeting beta-arrestin signaling and pharmaceutical compositions thereof, and their use in therapeutic applications of those disorders. | 05-31-2012 |
20120094864 | EXTRACELLULAR ALLOSTERIC INHIBITOR BINDING DOMAIN FROM A TYROSINE KINASE RECEPTOR - The present invention relates to an extracellular binding domain for an allosteric inhibitor, whereby said binding domain is derived from a single membrane span tyrosine kinase receptor. More specifically, the invention relates to an extracellular domain derived from a Fibroblast Growth Factor Receptor (FGFR). It further relates to the use of this domain for the identification of similar domains in the extracellular part of other tyrosine kinase receptors, and to a screening method for identification of a small compound allosteric inhibitor. | 04-19-2012 |
20120029174 | METHODS FOR PRODUCING SUBSTANTIALLY HOMOGENEOUS HYBRID OR COMPLEX N-GLYCANS IN METHYLOTROPHIC YEASTS - The present invention provides methods for effectively and efficiently converting methylotrophic yeast's heterogeneous high mannose-type N-glycosylation to mammalian-type N-glycosylation by disruption of an endogenous glycosyltransferase gene (OCH1) and step-wise introduction of heterologous glycosidase and glycosyltransferase activities. Each engineering step includes a number of stages: transformation with an appropriate vector, cultivation of a number of transformants, performance of sugar analysis and heterologous protein expression analysis, and selection of a desirable clone. The selected clone is then subjected to the next engineering step. | 02-02-2012 |
20120023624 | MEANS AND METHODS FOR MEDIATING PROTEIN INTERFERENCE - The present invention belongs to the field of functional proteomics and more particularly to the field of protein aggregation. The invention discloses a method for interfering with the function of a target protein and uses a non-naturally, user-designed molecule, designated as interferor, that has a specificity for a target protein and which induces aggregation upon contact with said target protein. The present invention also discloses such interferor molecules and their use in agrobiotech applications. | 01-26-2012 |
20120022135 | PHD2 INHIBITION FOR BLOOD VESSEL NORMALIZATION, AND USES THEREOF - A key function of blood vessels, to supply oxygen, is impaired in tumors because of abnormalities in their endothelial lining. PHD proteins serve as oxygen sensors and may regulate oxygen delivery. Therefore the role of endothelial PHD2 in vessel shaping by implanting tumors in PHD2 | 01-26-2012 |
20120005774 | USE OF TREHALASE TO OBTAIN DROUGHT RESISTANCE IN PLANTS - The present invention relates to the use of trehalase to obtain drought and/or salt resistance in plants. More specifically, it relates to genetically modified constructs, transformed into plants and resulting in overexpression of trehalase, whereby the transformed plants show a significantly better drought resistance during the drought period, and a better recovery when water is supplied after the drought period. | 01-05-2012 |
20110262348 | Selective targeting of intratumoral cells - The present invention relates to the field of tumor growth and biology. The invention relates to activities and characteristics of tumor-associated macrophages, and uses of such for the diagnosis and treatment of cancer and tumor growth. | 10-27-2011 |
20110250209 | INHIBITION OF PLGF TO TREAT PHILADELPHIA CHROMOSOME POSITIVE LEUKEMIA - The present application relates to the field of leukemias, and more in particular to how P1 GF inhibition can help to treat Philadelphia chromosome positive (Ph+) leukemias. Methods are provided for treating Ph+ leukemias by administering P1 GF inhibitors. Also disclosed are uses of P1 GF inhibitors in the treatment of Ph+ leukemias, or for the preparation of a medicament against Ph+ leukemias. | 10-13-2011 |
20110244011 | SPECIFIC DELIVERY OF AGROCHEMICALS - The present invention relates to specific delivery of agrochemicals to plants. More specifically, it relates to a composition, essentially consisting of a targeting agent comprising at least one binding domain that specifically binds to a binding site on an intact living plant and an agrochemical or a combination of agrochemicals. The present invention relates further to a binding domain that specifically binds the binding site on an intact living plant. More specifically, it relates to binding domains comprising an amino acid sequence that comprises four framework regions and three complementary determining regions, or any suitable fragment thereof, whereby the binding domains are capable to bind or retain a carrier onto a plant. In one preferred embodiment, the invention relates to binding domains which specifically bind trichomes, stomata, cuticle, lenticels, thorns, spines, root hairs, or wax layer. The invention relates further to a method for delivery of agrochemicals to a plant, for improving the deposition of agrochemicals on a plant, and for retaining the agrochemicals on a plant, using targeting agents comprising the binding domains, and to a method for protecting a plant against biotic or abiotic stress or controlling plant growth using the same. Also, the invention relates to a method for manufacturing a specifically targeting agrochemical carrier. | 10-06-2011 |
20110191913 | CELLS PRODUCING GLYCOPROTEINS HAVING ALTERED GLYCOSYLATION PATTERNS AND METHOD AND USE THEREOF - The present application relates to the field of glyco-engineering, more specifically to eukaryotic cells wherein both an endoglucosaminidase and a glycoprotein are present. These cells can be used to deglycosylate or partly deglycosylate the (exogenous) glycoprotein, in particular without the need for adding an extra enzyme. Methods are also provided for the application of these cells in protein production. According to one specific aspect, the eukaryotic cells and methods are glyco-engineered yeast cells in which additionally at least one exogenous enzyme needed for complex glycosylation is present, e.g. allowing easier separation of differentially glycosylated glycoproteins. | 08-04-2011 |
20110184049 | LIVER-SPECIFIC NUCLEIC ACID REGULATORY ELEMENTS AND METHODS AND USE THEREOF - The present invention relates to nucleic acid regulatory elements that are able to enhance liver-specific expression of genes, methods employing these regulatory elements and uses of these elements. Expression cassettes and vectors containing these nucleic acid regulatory elements are also disclosed. The present invention is particularly useful for applications using gene therapy. | 07-28-2011 |
20110162109 | Plants Having Modified Growth Characteristics and a Method for Making the Same - The present invention relates generally to the field of molecular biology and concerns a method for improving various economically important growth characteristics in plants. More specifically, the present invention concerns inter alia a method for modifying growth characteristics in plants by modulating expression in a plant of a nucleic acid encoding a HUB1 (Histone Monoubiquitination 1) polypeptide or encoding another protein useful in the methods of the present invention. The modified growth characteristics comprise a modification of light regulated phenotypes, such as modified circadian clock and/or circadian clock responses, or modified plant architecture. | 06-30-2011 |
20110136240 | DIAGNOSTIC TEST FOR THE DETECTION OF EARLY STAGE LIVER CANCER - The invention provides methods and kits to detect early stage hepatocellular carcinoma or a change in the gradation of hepatocellular carcinoma in mammals. The diagnostic marker is based on the profiling and identification of diagnostic carbohydrates present in a body fluid such as blood serum. | 06-09-2011 |
20110104183 | USE OF SIP1 AS DETERMINANT OF BREAST CANCER STEMNESS - The present invention relates to the diagnosis and treatment of cancer. More specifically, it relates to the use of SIP1 nucleic acid and/or protein for the detection of breast cancer stem cells, and the repression of the gene and/or the inactivation of the protein to repress the differentiation of cells into cancer cells and to inhibit metastasis of breast cancer tumors. | 05-05-2011 |
20110100816 | BLOOD SERUM MARKER FOR DETECTION AND DIAGNOSIS OF ALZHEIMER'S DISEASE - The present invention relates to a blood marker for early detection and diagnosis of Alzheimer's disease. More specifically, it relates to an analysis of the protein glycan profile in the blood, and the identification of specific peak ratio's when compared to healthy aged matched subjects that are typical for Alzheimer's dementia. | 05-05-2011 |
20110092374 | METHODS FOR PRODUCING SUBSTANTIALLY HOMOGENEOUS HYBRID OR COMPLEX N-GLYCANS IN METHYLOTROPHIC YEASTS - The present invention provides methods for effectively and efficiently converting methylotrophic yeast's heterogeneous high mannose-type N-glycosylation to mammalian-type N-glycosylation by disruption of an endogenous glycosyltransferase gene (OCH1) and step-wise introduction of heterologous glycosidase and glycosyltransferase activities. Each engineering step includes a number of stages: transformation with an appropriate vector, cultivation of a number of transformants, performance of sugar analysis and heterologous protein expression analysis, and selection of a desirable clone. The selected clone is then subjected to the next engineering step. | 04-21-2011 |
20110078825 | Modulation of plant cell number - The invention relates to the use of the ANG4 gene, or a variant thereof, to modulate the cell number of a plant organ. The modulation can be used to increase the plant biomass, or to adapt the plant architecture. | 03-31-2011 |
20110071085 | USE OF SURVIVIN TO TREAT KIDNEY FAILURE - The present invention relates generally to methods of for the prevention and treatment for renal disease. In particular, the invention relates to methods of prevention and treatment of mammals, including humans, which are at risk of developing renal failure. This is generally in the field of treatment or prevention of acute renal failure by administration of the anti-apoptotic molecule survivin. The invention also includes the treatment of kidney transplants (renal allografts) to prolong survival of the graft during cold ischemia and immediately after transplantation. | 03-24-2011 |
20110065638 | NOVEL CRUSTACEAN ANDROGENIC GLAND HORMONE - The present invention relates to a novel crustacean androgenic gland hormone. More specifically, the invention relates to an androgenic gland hormone derived from | 03-17-2011 |
20110038887 | Novel Vaccine Against Trypanosoma Cruzi Infection - The present invention relates to a vaccine against | 02-17-2011 |
20110033911 | Episomal fusion gene - The present invention relates to an episomal structure expressing a functional oncogene, whereby said oncogene is a fusion gene of two chromosomal gene fragments. More specifically, the invention relates to a NUP214-ABL1 fusion product, important in the development of T-cell acute lymphoblastic leukemia, to methods to detect the fusion and to methods to prevent the oncogenic activity of said fusion product. | 02-10-2011 |
20110021378 | NUCLEIC ACIDS OF PICHIA PASTORIS AND USE THEREOF FOR RECOMBINANT PRODUCTION OF PROTEINS - The present invention provides the genome sequence of | 01-27-2011 |
20100322967 | B CELL TOLERANCE INDUCTION - The present invention relates to the induction of immune tolerance, by a novel method of induction of IL-10 production in B cells, whereby said B cells can be loaded with antigen before, during or after the induction of the IL-10 production. More specifically, the invention relates to the transduction of the B cell with a retroviral vector encoding an antigen, whereby the retroviral envelop induces IL-10 production in the B cell by activation the TLR2 receptor, in combination with its viral receptor. | 12-23-2010 |
20100267084 | PROTEIN GLYCOSYLATION MODIFICATION IN METHYLOTROPHIC YEAST - The present invention provides genetically engineered strains of | 10-21-2010 |
20100204309 | OLIGONUCLEOTIDE COMPOSITIONS FOR THE TREATMENT OF ALZHEIMER'S DISEASE - The invention relates to the identification of microRNAs whose expression is diminished in neurodegenerative disorders. In particular, the identified microRNAs can be used for the downregulation of the beta-secretase (BACE1) in mammalian brain and hence for the treatment of Alzheimer's disease. | 08-12-2010 |
20100152253 | NON-STEROIDAL BRASSINOSTEROID MIMETIC - The present invention relates to non-steroidal mimetics of brassinosteroids. More specifically, it relates to non-steroidal monocyclic compounds, capable of rescuing the brassinosteroid receptor null mutation bri1-116. Preferably, said compounds are low molecular weight, monocyclic halogenated compound. | 06-17-2010 |
20100130586 | DIAGNOSIS AND TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA - The present invention relates to the field of biotechnological means to diagnose or treat T-cell acute lymphoblastic leukaemia. More particularly, the invention relates to methods to diagnose T-cell acute lymphoblastic leukaemia via determining the presence of a duplication of the MYB gene in cells taken from patients. The invention further relates to inhibitors capable of neutralizing the biological activity of MYB alone, or in combination with inhibitors capable of neutralizing the biological activity of NOTCH1, which can be used to treat T-cell acute lymphoblastic leukaemia. | 05-27-2010 |
20090298066 | Sex-Specific Marker for Shrimps and Prawns - The present invention relates to a sex-specific marker for shrimps and prawns. More specifically, it relates to a sex-specific PCR-based molecular marker, derived from | 12-03-2009 |
20090263863 | MODIFICATION OF PROTEIN GLYCOSYLATION IN METHYLOTROPHIC YEAST - The present invention relates to methods and genetically engineered methylotrophic yeast strains for producing glycoproteins with mammalian-like glycosylation. The present invention also relates to vectors useful for generating methylotrophic yeast strains capable of producing glycoproteins with mammalian-like glycosylation. Glycoproteins produced from the genetically engineered methylotrophic yeast strains are also provided. | 10-22-2009 |
20090222952 | Plants Having Improved Growth Characteristics And A Method For Making The Same - The present invention concerns a method for increasing plant yield and/or increased stress resistance by decreasing the level of activity of a DEL1 polypeptide. One such method comprises introducing into a plant a nucleic acid comprising a variant DEL1 nucleic acid. Another method comprises downregulating expression of a DEL1 gene. The invention also relates to transgenic plants having introduced therein a variant DEL1 nucleic acid thereof, which plants have increased yield and/or increased stress resistance relative to control plants. The present invention also concerns a novel DEL1 protein and its encoding sequence, and constructs useful in the methods of the invention. | 09-03-2009 |
20090151021 | Novel Stress-Related MicroRNA Molecules and Uses Thereof - Naturally occurring and synthetic novel stress-related miRNAs are provided which can be used to modify the stress tolerance of plants. | 06-11-2009 |
20090047294 | Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration - The invention relates to the field of muscle pathologies, more particularly to the field of diseases where skeletal muscle degeneration occurs. The invention describes transgenic mice that do not produce prolyl-hydroxylase-1, -2 or -3. It is revealed that the phenotype of the prolyl-hydroxylase 1 knock-out mouse is characterized by a protection of skeletal muscle atrophy due to a variety of muscle damages, especially ischemic insults. The invention thus relates to the use of molecules that can bind to prolyl-hydroxylase-1 for the prevention and/or treatment of skeletal muscle degeneration. | 02-19-2009 |
20090012275 | Means and methods for mediating protein interference - The invention belongs to the field of functional proteomics and, more particularly, to the field of protein aggregation. Described are methods for interfering with the function of a target protein and uses a non-naturally, user-designed molecule, designated as interferor, that has a specificity for a target protein and that induces aggregation upon contact with the target protein. The invention also discloses such interferer molecules and their use in therapeutic applications. | 01-08-2009 |